Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial

Eur J Neurol. 2001 Jan;8(1):81-5. doi: 10.1046/j.1468-1331.2001.00181.x.


The aim of the study was to assess the safety and feasibility of a clinical trial on the effect of vinpocetine, a synthetic ethyl ester of apovincamine, in acute ischaemic stroke. Thirty consecutive patients with computed tomography verified diagnosis of acute ischaemic stroke, who could receive drug treatment within 72 h of stroke onset, were enrolled. The patients were randomly allocated to receive either low-molecular weight dextran alone or in combination with vinpocetine. Poor outcome was defined as being dead or having a Barthel index of < 70 or a Rankin score of 3--5. Intention-to-treat analysis was applied. One-tenth of all hospitalized patients with acute ischaemic stroke were eligible for the trial. Thirty eligible patients were treated with either low-molecular weight dextran alone (mean age 57.9 +/- 11.6 years, n = 15) or in combination with vinpocetine (mean age 60.8 +/- 6.6 years, n = 15). The two treatment groups were comparable with respect to major prognostic variables. A relative risk (RR) reduction of poor outcome at 3 months follow-up was 30% (RR = 0.7; 95% confidence interval [CI] 0.1--3.4), as defined by the modified Barthel Index, and 60% as defined by the modified Ranking score (RR = 0.4, 95% CI: 0.1--1.7). The National Institute of Health (NIH--NINDS) Stroke Scale score was marginally significantly better in the vinpocetine treated group at 3 months of follow-up (P = 0.05, ANOVA). No significant adverse effects were seen. This pilot study shows that a full-scale randomized double-blind, placebo-controlled trial of vinpocetine treatment in acute ischaemic stroke is feasible and warranted.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Aged
  • Brain Ischemia / complications*
  • Dextrans / chemistry
  • Dextrans / therapeutic use
  • Drug Combinations
  • Feasibility Studies
  • Female
  • Humans
  • Male
  • Middle Aged
  • Molecular Weight
  • Neuroprotective Agents / therapeutic use*
  • Pilot Projects
  • Severity of Illness Index
  • Single-Blind Method
  • Stroke / drug therapy*
  • Stroke / etiology*
  • Stroke / physiopathology
  • Treatment Outcome
  • Vinca Alkaloids / therapeutic use*


  • Dextrans
  • Drug Combinations
  • Neuroprotective Agents
  • Vinca Alkaloids
  • vinpocetine